Locust Walk

A global investment bank that partners with founders, executives, and board members to drive strategic transactions and create newcos to finance innovation.

[Locust Walk @LocustWalkPtrs]

Does JPM week actually predict the year ahead in biopharma? Locust Walk analyzed multi-year data across licensing, M&A, and capital markets.

Takeaway: JPM is a strong signal for licensing momentum, but not for M&A or deal value trends.

Full analysis: https://t.co/PDLAEgdOdj

[Locust Walk @LocustWalkPtrs]

Public biopharma capital markets bounced back in Q4 2025, up 187% from Q2 lows to $16.7B, a four-year high! Follow-on offerings fueled the rebound, signaling strong investor appetite and confidence in valuations.

Full Locust Walk 2025 Report: https://t.co/z36xbuQC9i

[Locust Walk @LocustWalkPtrs]

China-based biopharma sellers overtook the US in 2025 as the top source of global licensing deal value, now representing ~48% of total value.

Fewer deals, but much bigger economics, signal China’s growing role as a global innovation engine.

2025 Report: https://t.co/z36xbuR9YQ

[Locust Walk @LocustWalkPtrs]

Locust Walk’s 2025 Year-In-Review Report is out. Renewed optimism, disciplined risk-taking, and stronger public markets drove M&A, financing, and venture to multi-year highs.

Download: https://t.co/z36xbuR9YQ

#Biopharma #LifeSciences #Deals #Financing #MarketTrends

[Locust Walk @LocustWalkPtrs]

@LocustWalkPtrs @GeoffMeyerson & Sophie Katz shared their insights in an article for Life Science Leader titled “Insights on Today's Biotech Market Conditions”.

We invite you to read the article to learn what advise Locust Walk has for biotech CEOs: https://t.co/ma1oK9x5dF

[Locust Walk @LocustWalkPtrs]

In '20/'21 biotech had an aggressive short-lived boom. Geoff noted “There was an enormous amount of companies that got funded on a dream, & ultimately 20 technologies focused on CRISPR-Cas-pick-your-number is not sustainable. The world doesn’t need that many companies like that.”

[Locust Walk @LocustWalkPtrs]

@endpts sat down with @GeoffMeyerson to take closer look at the biotech sector's complex funding landscape amidst recent headlines of mega-raises.

Read the full article: https://t.co/X6GoxaJ7su

[Locust Walk @LocustWalkPtrs]

Despite positive signs, investors are displaying greater discipline, focusing on product candidates with substantial market potential & more advanced data. Geoff projects recovery will not be material for another year or more given the macroeconomic environment’s headwinds.

[Locust Walk @LocustWalkPtrs]

Interested in #RNA research and development? The Locust Walk RNA Innovation Conference will be hosted virtually May 9, 2023, 10am-4pm ET.

Investors, strategic partners, RNA-focused companies, and academic innovators interested in attending can contact [email protected].

[Locust Walk @LocustWalkPtrs]

Tune in to Biotalk, our #podcast for #biotech leaders. This episode features Andrew Allen, Co-Founder, President, & CEO of @gritstonebio.

Listen to Biotalk here:  https://t.co/whSADiqZQ1

[Locust Walk @LocustWalkPtrs]

What are the three basic forces that shaped the financial landscape for #biotech in 2021 and why will they drive the market in 2022? @LocustWalkPtrs's @GeoffMeyerson provides his insights to @STAT’s @sheridan_kate.

Click here to read the full article: https://t.co/Mzmqwi4lc4

[Locust Walk @LocustWalkPtrs]

Meet Yen Ting Chen! Based in our #Tokyo office, Yen Ting leads our delivery and outreach efforts across Asia. Yen Ting plays an instrumental role in helping our global clients establish productive partnerships in China and Japan.

#global #companyculture #lifesciences

[Locust Walk @LocustWalkPtrs]

We are proud to congratulate our team members who have received #promotions! Thank you for all your hard work & dedication to our team & our clients. #EnjoyTheRide

We are thrilled by our team’s growth & accomplishments in 2021 & are excited to see all that is to come in 2022!

[Locust Walk @LocustWalkPtrs]

Uncommon strategy before, this is now viewed as de rigueur prior to a #biopharma #IPO.

Click below to read what biopharmas need to know to structure an optimum crossover round.

https://t.co/Fn1vpRgixB

[Locust Walk @LocustWalkPtrs]

In 2021, @LocustWalkPtrs most download white paper was: Crossover Evolution: The Evolving Role of the Crossover Financing Round. In March of 2020, biotech indices quickly nose-dived but that was temporary. #Crossover financing rounds were a leading trend in that recovery.

[Locust Walk @LocustWalkPtrs]

The @LocustWalkPtrs #Boston office gathered for a white elephant gift exchange & ugly sweater contest. Can you guess who won?

During this busy time of the year, it’s important to pause to #EnjoyTheRide, celebrate the year’s work, & look forward to what’s to come. #LocustWalklife

[Locust Walk @LocustWalkPtrs]

Our team is dedicated to the Locust Walk mission to walk with our clients to improve human health globally. #Boston #NewYork #SanFrancisco #London #Japan

We are not done growing! To view our current openings: https://t.co/6mov1xglUM

#LocustWalklife #EnjoyTheRide #lifesciences

[Locust Walk @LocustWalkPtrs]

As we start to wrap up the year, we want to celebrate the growth of our team in 2021. @LocustWalkPtrs welcomed 23 new members to our team this year! Everyone hit the ground running and their impact was felt from the start. #Thankyou

[Locust Walk @LocustWalkPtrs]

@LocustWalkPtrs is #hiring for Associates in #Boston #NewYork #SanFrancisco & #London! Associates play a key role in leading the firm’s engagements & participating in the firm’s new business development activities. Come #EnjoytheRide!

Learn more: https://t.co/6mov1xglUM

[aptihealth @aptihealth]

The holidays bring joy and happiness as well as frustration and stress. This holiday season you may have many things to take care of but the most important is yourself. @APA’s Holiday Stress Resource Center has things you can do to minimize holiday stress. https://t.co/i88oSTAMpB